STOCK TITAN
  1. Home
  2. Sec-filings
  3. VXRT
  4. [Form 4] Vaxart, Inc. Insider Trading Activity

Vaxart, Inc. (VXRT) director adds 10,000 shares in open‑market buy

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxart, Inc. director Watson W. Mark reported an open-market purchase of 10,000 shares of Common Stock on May 22, 2026 at $0.653 per share. Following this transaction, he directly holds 134,125 shares of Vaxart common stock.

Positive

  • None.

Negative

  • None.
Insider Watson W. Mark
Role null
Bought 10,000 shs ($7K)
Type Security Shares Price Value
Purchase Common Stock 10,000 $0.653 $7K
Holdings After Transaction: Common Stock — 134,125 shares (Direct, null)
Footnotes (1)
Shares purchased 10,000 shares Open-market purchase of Vaxart Common Stock
Purchase price $0.653 per share Price paid on May 22, 2026 transaction
Total direct holdings 134,125 shares Shares owned directly after the transaction
Net buy shares 10,000 shares Net-buy direction from transaction summary
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
net-buy financial
"netBuySellDirection: "net-buy""
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Watson W. Mark
(Last)(First)(Middle)
C/O VAXART, INC.
310 UTAH AVENUE, SUITE 150
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxart, Inc. [ VXRT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/22/2026P10,000A$0.653134,125D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Edward Berg, Attorney-in-Fact for W. Mark Watson05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Vaxart (VXRT) report for Watson W. Mark?

Vaxart reported that director Watson W. Mark made an open-market purchase of 10,000 shares of Common Stock. The transaction was disclosed on Form 4 and reflects a direct acquisition of Vaxart equity rather than a grant, gift, or tax-related withholding.

How many Vaxart (VXRT) shares did the director buy and at what price?

Watson W. Mark bought 10,000 Vaxart Common Stock shares at $0.653 per share. This open-market purchase increased his direct ownership position and represents a cash investment at that specific trading price on the transaction date.

What is Watson W. Mark’s total Vaxart (VXRT) holding after this transaction?

After the reported purchase, Watson W. Mark directly owns 134,125 shares of Vaxart Common Stock. This figure, disclosed in the Form 4, reflects his total direct holdings immediately following the 10,000-share open-market acquisition.

Was the Vaxart (VXRT) insider trade a buy or a sell?

The transaction was a buy, specifically an open-market purchase coded as “P” on Form 4. It involved acquiring 10,000 Vaxart Common Stock shares, increasing the director’s direct ownership to 134,125 shares after the trade was completed.

Does the Vaxart (VXRT) Form 4 show any derivative transactions?

The Form 4 data show no derivative transactions for this event. All reported activity relates to non-derivative Common Stock, with a single open-market purchase and no associated options exercises, conversions, gifts, or tax-withholding dispositions.